DEUCRAVACITINIB (has an active metabolite) | DEUCRAVACITINIB | ATC L04AF07
IMMUNOSUPPRESSANTS IMMUNOMODULATING AGENTS TYROSINE KINASE 2 (TYK2) ALLOSTERIC INHIBITOR TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | ORAL | Cmax 105.7 NANOMOLAR Tmax 2.5 HOUR F 99 PERCENT VD 140 LITER PPB 86 PERCENT Cl 2.4 LITER / HOUR HT 10 HOUR SOLUBILITY PH DEPENDENT DECREASES WITH INCREASING PH | TYROSINE KINASE 2 (TYK2) PDB 6NZP (CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH COMPOUND-11) LIGAND CODE = LB7 (link to the list of PDB complexes) Download experimental 3D coordinates of LB7 with added hydrogens | tyrosine kinase 2 (TYK2) UNIPROT P29597 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |